POSC

POSITRON CORP

3 filings tracked

healthcaremedical devicesMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 15

Net loss of $1.38M and widening gross loss due to inventory write-downs.

earnings miss

70%

bearishMay 15

Cost of sales increased 69% YoY, leading to a significant gross loss.

margin compression

80%

bearishMay 15

Convertible advance payable allows settlement at a 45% discount to market price.

dilution risk

60%

bullishMay 15

Repayment of $325,000 in related-party debt to reduce liabilities.

debt restructure

40%

bearishMay 15

Net loss of $1.38M and widening gross loss due to inventory write-downs.

earnings miss

70%

bearishMay 15

Cost of sales increased 69% YoY, leading to a significant gross loss.

margin compression

80%

bearishMay 15

Convertible advance payable allows settlement at a 45% discount to market price.

dilution risk

60%

bullishMay 15

Repayment of $325,000 in related-party debt to reduce liabilities.

debt restructure

40%

bearishMar 31

Net loss widened from $2.38M to $10.6M in one year.

earnings miss

90%

bearishMar 31

Gross loss expanded to $2.11M as cost of sales surged to 560% of revenue.

margin compression

80%

neutralMar 31

Raised $10M through common stock issuance in 2025 to extend runway.

capital raise

60%

bullishMar 31

Nearing completion of safety and performance testing for Affinity PET-CT FDA submission.

regulatory action

70%

Filing History

10-QMay 15, 2026

The Q1 2026 filing presents a classic high-risk, high-reward scenario centered on a single regulatory catalyst. Positron has successfully shifted its product strategy toward the Affinity PET-CT system and has secured the initial customer deposits to prove market demand. However, these operational wins are currently overshadowed by a looming liquidity crunch and a balance sheet that lacks the resilience to withstand further delays in FDA approval. Investors are essentially weighing the probability of a successful 510(k) amendment against the certainty of a continuing cash burn. While the partnership with Neusoft provides the necessary technological infrastructure, the company's reliance on related-party financing and the threat of dilution from convertible advances create a volatile environment. The overall impact of the filing is a stark reminder that until the first unit is delivered and revenue is recognized, Positron remains a speculative venture with significant solvency risks.

10-KMar 31, 2026

The 10-K filing presents a stark dichotomy between Positron's ambitious product roadmap and its precarious financial reality. On one side, the company is perfectly aligned with a high-growth clinical trend toward PET-CT imaging, backed by a strong OEM partner and a clear market gap. The potential to disrupt the nuclear cardiology market by lowering the cost of entry for advanced imaging is a compelling catalyst that could lead to exponential growth if the Affinity system achieves regulatory approval and commercial traction. However, the financial data suggests that the window for execution is narrow. The company is burning cash at an unsustainable rate and is almost entirely dependent on the capital markets to fund its path to FDA clearance. The transition from a service-heavy model to an equipment-sales model is the only viable path to profitability, but the current gross losses and declining service revenues create a race against time. Investors are essentially betting on the successful execution of a high-stakes regulatory milestone to save a company currently facing substantial doubt about its ability to continue as a going concern.